Group 1 - Jia Ying Pharmaceutical is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, having received a notice of case filing on May 28, 2025 [2] - ST United plans to acquire 100% of Run Tian Industrial through a combination of share issuance and cash payment, aiming to enhance its positioning as a comprehensive service provider in cultural tourism consumption [3] - Long Gao Co., Ltd. announced the restructuring of its controlling shareholder, Longyan Investment Development Group, which has established a new investment development group with a registered capital of 3 billion yuan [4] Group 2 - Sanyou Chemical's controlling shareholder intends to inject 100 million yuan into its subsidiary, Tangshan Sanyou Silicon Industry Co., Ltd., through a private agreement, without affecting the consolidation scope of the company [5] - ST Ji Pharmaceutical's stock will be delisted on May 29, 2025, due to a continuous closing price below 1 yuan for twenty trading days, triggering termination of listing rules [6] - Taiji Industrial plans to repurchase shares worth 100 million to 120 million yuan, with a maximum repurchase price of 10.38 yuan per share [7] Group 3 - China Energy Construction's subsidiary has won a bid for a coal power project worth approximately 14.586 billion yuan, marking a significant contract win [8][9]

关于收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日收到中 国证券监督管理委员会（以下简称"中国证监会"）的《立案告知书》（证监立案 字 0062025010 号），因公司涉嫌信息披露违法违规，根据《中华人民共和国证券 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 证券代码：002198 证券简称：嘉应制药 公告编号：2025-033 广东嘉应制药股份有限公司 公司将积极配合中国证监会的相关工作，并严格按照规定及监管要求履行信 息披露义务。公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》 和巨潮资讯网（http://www.cninfo.com.cn），公司相关信息均以在上述指定信息披 露媒体登载的公告为准。敬请广大投资者关注公司相关公告，理性投资，注意投 资风险。 特此公告。 广东嘉应制药股份有限公司董事会 2025 年 5 月 29 日 ...

Group 1 - Ningde Times participated in the completion of the Zeyuan Fund, with a total scale of 10.128 billion yuan, increasing by 50.42% from the previous announcement [3] - Zhongjin Gold's controlling shareholder plans to inject four companies into the company to resolve competition issues, including acquiring stakes in Inner Mongolia Jintao and others [4][5] - Keli Yuan plans to invest an additional 500 million yuan in a storage industry fund, increasing its total investment to 700 million yuan [6] Group 2 - China Shenhua intends to acquire 7.43% of the National Energy Group Financial Company for 2.929 billion yuan, which is expected to increase its net profit by 97 million yuan [7] - Weir Shares plans to issue H-shares and list on the Hong Kong Stock Exchange [8] - Hualan Shares is establishing a joint venture for Tibetan medicinal baths and plaster products, with a registered capital of 7 million yuan [15] Group 3 - Yunnan Copper plans to acquire 40% of Liangshan Mining through a share issuance, with the stock resuming trading on May 26 [10] - Ruishun Technology's subsidiary plans to establish a joint venture in Malaysia to provide automation solutions [11] - ST Quanwei's stock will be subject to additional risk warnings due to ongoing litigation involving a subsidiary [12] Group 4 - Hengfeng Information's controlling shareholder has terminated the agreement to transfer part of the company's shares, with no impact on control [13] - Huadian Technology's subsidiary has not yet commenced substantial construction on a polyurethane new materials project [14] - ST Yinjian will remove the delisting risk warning and some other risk warnings, changing its stock name [38] Group 5 - China Tonghao won approximately 3.789 billion yuan in contracts in the rail transit market from March to April [39] - Intercontinental Oil and Gas plans to invest about 848 million USD in the Iraq South Basra project [40][41] - Jiaying Pharmaceutical's subsidiary signed a contract for the development of a traditional Chinese medicine innovation project [42] Group 6 - Ruidong Intelligent signed a strategic cooperation agreement with Shunde Vocational and Technical College to enhance collaboration in technology [43] - Jiaojian Co. won a bid for a drainage project worth 225 million yuan [44] - Hengshun Vinegar's controlling shareholder plans to increase its stake in the company by 50 to 100 million yuan [45]

Group 1 - Zhongjin Gold plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues, acquiring stakes of 49.34%, 80%, 70%, and 70% respectively [3] - Keli Yuan intends to invest an additional 500 million yuan in a storage industry fund, increasing its total commitment from 200 million yuan to 700 million yuan, holding 49.93% of the fund [4] - China Shenhua plans to acquire a 7.43% stake in the National Energy Group Financial Company for 2.929 billion yuan, which is expected to increase its net profit by 97 million yuan [5] Group 2 - Weier Co. plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders [6] - China Communication Signal plans to invest approximately 3.789 billion yuan in 11 major rail transit projects, accounting for 11.67% of its audited revenue for 2024 [8] - Intercontinental Oil and Gas intends to invest approximately 848 million USD in the Iraq South Basra Integrated Project, with a total investment of about 1.266 billion USD [9] Group 3 - Jiaying Pharmaceutical's subsidiary signed a technology development contract with Hunan University of Chinese Medicine to develop a new traditional Chinese medicine [10] - Ruide Intelligent signed a strategic cooperation agreement with Shunde Vocational and Technical College to enhance collaboration in technology and talent development [11] - Jiaojian Co. and its partners won a bid for a drainage project worth 225 million yuan, with an expected contribution of 101 million yuan to the company's revenue [12] Group 4 - Hengshun Vinegar's controlling shareholder plans to increase its stake in the company by investing between 50 million and 100 million yuan [14] - Changhua Group's shareholder platform intends to reduce its stake by up to 3%, amounting to a maximum of 14.1 million shares [15] Group 5 - Yunzhongma plans to raise no more than 640 million yuan through a private placement to fund projects for producing DTY yarn and high-performance leather base fabric [17]

Agreement Overview - Guangdong Jiaying Pharmaceutical Co., Ltd. signed a technology development contract with Hunan University of Chinese Medicine, establishing a cooperative relationship for the development of a traditional Chinese medicine innovation drug, "Juanbi Lijieqing Granules" [1][2] - The contract does not constitute a related party transaction or a major asset restructuring, thus does not require approval from the shareholders or board of directors [1][2] Contract Details - The contract aims to develop "Juanbi Lijieqing Granules," which is based on a clinically effective formula used for many years [2] - Hunan University of Chinese Medicine will provide the traditional Chinese medicine formula and technical support, while Jiaying Pharmaceutical will conduct all necessary research for new drug registration [2][3] - The project includes pharmacological and toxicological studies, clinical research, and the preparation of registration documents [3][4] Project Responsibilities - Hunan University of Chinese Medicine is responsible for providing the formula and clinical technical support, including clinical positioning and trial design [4] - Jiaying Pharmaceutical will handle the pharmaceutical research, pharmacology, toxicology, and clinical studies necessary for the drug registration [4] Intellectual Property and Profit Sharing - Both parties will jointly apply for patents for any technical achievements resulting from the contract [4] - If the technology is successfully commercialized, profits will be shared based on market valuation or through preferential purchasing by Jiaying Pharmaceutical [4] Impact on the Company - The collaboration is expected to enrich the existing research pipeline and enhance research efficiency, aligning with the company's long-term development strategy and benefiting shareholders [5]

证券代码：002198 证券简称：嘉应制药 公告编号：2025-032 广东嘉应制药股份有限公司 关于子公司签署《技术开发合同》的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 近日，广东嘉应制药股份有限公司（以下简称"公司"）全资子公司嘉应制药 （湖南）有限公司（以下简称"子公司"或"乙方"）与湖南中医药大学（以下简称 "甲方"）签署《技术开发合同》。 根据《深圳证券交易所股票上市规则》《公司章程》等相关规定，本次合同 的签署不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重 大资产重组，无需提交股东会和董事会审议。 二、合同签署概况 单位名称：湖南中医药大学 法定代表人：易刚强 注册资本：198,931 万元 注册地址：长沙市岳麓区含浦科教产业园学士路 300 号 宗旨和业务范围：培养高等学历医药人才，促进卫生事业发展。 中医药学 科大专、本科、研究生、硕士研究生、博士研究生学历教育、博士后培养相关科 学研究、继续教育、专业培训、学术交流相关社会服务。 本次签署的《技术开发合同》确立了双方的合作关系，具体实施进 ...

广东嘉应制药股份有限公司 证券代码：002198 证券简称：嘉应制药 公告编号：2025-031 截至本公告披露日，史俊平先生未持有公司股票，公司及公司董事会对史俊 平先生任职财务总监期间为公司发展所做的贡献表示衷心感谢！公司将按照相关 规定尽快完成财务总监的选聘工作，并及时履行信息披露义务。 特此公告。 广东嘉应制药股份有限公司董事会 2025 年 5 月 20 日 关于公司财务总监辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）董事会于近日收到公司财务 总监史俊平先生提交的书面辞职报告。史俊平先生因个人原因辞去公司财务总监 职务，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》《公司章程》等相关规定，其辞职报 告自送达董事会之日起生效，辞任后不再担任公司任何职务，也不会影响公司的 正常运行。 ...

（一）会议召开情况 2024 年度股东大会决议公告 证券代码：002198 证券简称：嘉应制药 公告编号：2025-030 广东嘉应制药股份有限公司 2024 年度股东大会决议公告 本公司及全体董事、监事、高级管理人员保证公告内容真实、准确和完整， 公告不存在虚假记载、误导性陈述或者重大遗漏。 特别提示： 本次股东大会未出现否决议案的情况，也不存在涉及变更前次股东大会决议的 情形。 一、会议召开和出席情况 2、现场会议召开地点：广东省梅州市东升工业园B区广东嘉应制药股份有限公 司会议室。 3、会议表决方式：采用现场表决与网络投票相结合的方式。 4、会议召集人：公司董事会。 5、会议主持人：董事长李能。 6、本次股东大会召集、召开程序符合《公司法》《上市公司股东大会规则》 等法律、法规、规范性文件和《公司章程》的规定。 1 2024 年度股东大会决议公告 1、会议召开的时间： （1）现场会议：2025年5月16日（星期五）下午14：30； （2）网络投票：2025年5月16日。 通过深交所交易系统进行网络投票的具体时间为2025年5月16日上午9:15至 9:25，9：30至11：30，下午13：00至15：0 ...

湖南启元律师事务所 关于广东嘉应制药股份有限公司 2024年年度股东大会的 法律意见书 致：广东嘉应制药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受广东嘉应制药股份有限公司 （以下简称"公司"）的委托，指派律师出席了公司 2024 年年度股东大会（以下 简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员及 召集人的资格、表决程序和表决结果的合法有效性进行律师见证，并发表本法律 意见。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）等我国现行法律、法规、规范 性文件以及《广东嘉应制药股份有限公司章程》（以下简称"《公司章程》"） 的有关规定出具本法律意见书。 为出具本法律意见书，本所声明如下： （一）本所出具本法律意见书是基于公司已承诺所有提供给本所的文件的正 本以及经本所查验与正本保持一致的副本均为真实、完整、可靠，无隐瞒、虚假 或重大遗漏之处。 （二）本所遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对本法 律意见书出具日以前已经发生或者存在的事实进行了充分的核查验证，保证本法 律意见书所认定的事实真实、准确 ...

Core Viewpoint The Guangdong Jiaying Pharmaceutical Co., Ltd. is preparing for its 2024 Annual General Meeting, focusing on various proposals including financial reports, profit distribution plans, and corporate governance matters. Group 1: Meeting Details - The meeting is scheduled for May 16, 2025, at 14:30 in Meizhou, Guangdong Province [5] - Attendees will include shareholders, company directors, supervisors, senior management, and invited guests [5] Group 2: Proposals for Review - Proposal 1: Review of the 2024 Annual Report and its summary [6] - Proposal 2: Review of the 2024 Financial Settlement Report, audited by Zhonghua Accounting Firm [7] - Proposal 3: Profit distribution plan for 2024, which proposes no cash dividends or stock bonuses [9][11] - Proposal 4: Review of the 2024 Board of Directors' Work Report, highlighting operational achievements and challenges [14] - Proposal 5: Review of the 2024 Supervisory Board's Work Report, detailing compliance and oversight activities [32] - Proposal 6: Confirmation of 2024 director remuneration and proposal for 2025 remuneration [36] - Proposal 7: Request for a comprehensive credit limit of up to RMB 200 million from banks for operational needs [37] - Proposal 8: Review of daily related party transactions for 2024 and projections for 2025 [40] Group 3: Financial Performance and Strategy - The company reported a net profit of RMB 16,346,842.23 for 2024, with no cash dividends proposed due to financial constraints and strategic investments [9][11] - The company aims to enhance its product portfolio and reduce reliance on a single product line, particularly in response to market fluctuations affecting its main products [11][12] - The company plans to invest in research and development to diversify its offerings and improve market competitiveness [29][30] Group 4: Corporate Governance and Compliance - The company has established a robust internal control system to ensure compliance with laws and regulations, maintaining transparency and protecting shareholder interests [33][35] - The Supervisory Board has actively monitored the company's operations, ensuring adherence to legal and regulatory standards [32][34]